X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (974) 974
Publication (52) 52
Newsletter (15) 15
Book Review (6) 6
Magazine Article (4) 4
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (878) 878
female (471) 471
male (455) 455
goserelin (446) 446
goserelin - administration & dosage (437) 437
middle aged (418) 418
adult (358) 358
prostatic neoplasms - drug therapy (351) 351
aged (314) 314
oncology (276) 276
goserelin - therapeutic use (263) 263
antineoplastic combined chemotherapy protocols - therapeutic use (239) 239
antineoplastic agents, hormonal - administration & dosage (236) 236
index medicus (234) 234
antineoplastic agents, hormonal - therapeutic use (206) 206
breast neoplasms - drug therapy (200) 200
treatment outcome (196) 196
prostate cancer (163) 163
buserelin - analogs & derivatives (162) 162
prostatic neoplasms - pathology (150) 150
aged, 80 and over (149) 149
gonadotropin-releasing hormone - agonists (141) 141
goserelin - adverse effects (129) 129
delayed-action preparations (127) 127
cancer (125) 125
breast cancer (124) 124
obstetrics & gynecology (124) 124
buserelin - administration & dosage (120) 120
testosterone - blood (120) 120
buserelin - therapeutic use (119) 119
premenopause (117) 117
care and treatment (116) 116
chemotherapy, adjuvant (116) 116
follow-up studies (116) 116
urology & nephrology (114) 114
drug administration schedule (112) 112
prospective studies (112) 112
carcinoma (107) 107
tamoxifen (105) 105
therapy (104) 104
prostate-specific antigen - blood (101) 101
luteinizing hormone - blood (97) 97
androgen antagonists - administration & dosage (96) 96
prostatic neoplasms - blood (96) 96
time factors (96) 96
flutamide - administration & dosage (95) 95
tamoxifen - administration & dosage (95) 95
women (94) 94
leuprolide - administration & dosage (92) 92
chemotherapy (89) 89
neoplasm staging (89) 89
androgen antagonists - therapeutic use (87) 87
antineoplastic agents, hormonal - adverse effects (87) 87
gonadotropin-releasing hormone - analogs & derivatives (84) 84
disease-free survival (83) 83
estradiol - blood (80) 80
breast neoplasms - pathology (78) 78
orchiectomy (77) 77
combined modality therapy (76) 76
follicle stimulating hormone - blood (76) 76
adenocarcinoma - drug therapy (71) 71
testosterone (70) 70
anilides - administration & dosage (69) 69
nitriles - administration & dosage (69) 69
prostatic neoplasms - mortality (67) 67
injections, subcutaneous (65) 65
radiotherapy (64) 64
drug therapy, combination (63) 63
endocrinology & metabolism (63) 63
endometriosis - drug therapy (62) 62
prostatic neoplasms - radiotherapy (61) 61
research (60) 60
trial (60) 60
goserelin - pharmacology (59) 59
menopause (59) 59
survival rate (59) 59
antineoplastic combined chemotherapy protocols - adverse effects (58) 58
prostatic neoplasms - surgery (58) 58
health aspects (56) 56
hormones (53) 53
animals (52) 52
prognosis (52) 52
prostatic neoplasms - therapy (52) 52
quality of life (52) 52
estrogen (51) 51
radical prostatectomy (51) 51
antineoplastic combined chemotherapy protocols - administration & dosage (50) 50
drug therapy (50) 50
leuprolide - therapeutic use (50) 50
cyclophosphamide (49) 49
endocrine therapy (48) 48
pregnancy (48) 48
retrospective studies (46) 46
survival analysis (46) 46
flutamide (44) 44
neoadjuvant therapy (44) 44
breast neoplasms - surgery (43) 43
cyclophosphamide - administration & dosage (42) 42
endometriosis (42) 42
postmenopausal women (42) 42
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (885) 885
Japanese (44) 44
German (16) 16
French (14) 14
Italian (11) 11
Chinese (9) 9
Bulgarian (5) 5
Russian (4) 4
Spanish (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Korean (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 9, pp. 840 - 849
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2015, Volume 26, Issue 2, pp. 313 - 320
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 14, pp. 1314 - 1325
Despite theoretical benefits of intermittent as compared with continuous androgen-deprivation therapy in patients with metastatic prostate cancer, intermittent... 
MEDICINE, GENERAL & INTERNAL | THERAPY | CLINICAL-TRIAL | FLUTAMIDE | QUALITY-OF-LIFE | SUPPRESSION | CARCINOMA | LEUPROLIDE | Confidence Intervals | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis - drug therapy | Penile Erection - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Goserelin - adverse effects | Prostatic Neoplasms - drug therapy | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Tosyl Compounds - adverse effects | Anilides - administration & dosage | Survival Analysis | Quality of Life | Aged | Androgen Antagonists - administration & dosage | Nitriles - adverse effects | Usage | Care and treatment | Patient outcomes | Androgen suppression therapy | Drug therapy | Prostate cancer | Methods | Cancer | Statistical analysis | Mental disorders | Prostate-specific antigen | Clinical trials | Patients | Survival | Quality of life | Metastases | Androgens | Castration | Stem cells | Luteinizing hormone | Prostate
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2015, Volume 33, Issue 4, pp. 332 - 339
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2017, Volume 23, Issue 8, pp. 1974 - 1980
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2003, Volume 95, Issue 24, pp. 1833 - 1846
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 8/2013, Volume 141, Issue 1, pp. 119 - 123
The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown. In this... 
Metastatic disease | Medicine & Public Health | Endocrine therapy | Oncology | Gonadotropin-releasing hormone analog | Male breast cancer | Letrozole | ONCOLOGY | AROMATASE INHIBITION | ESTROGEN | BUSERELIN | EXPRESSION | Triazoles - administration & dosage | Cyclophosphamide - administration & dosage | Neoplasms, Hormone-Dependent - radiotherapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Breast Neoplasms, Male - surgery | Estrogens | Humans | Middle Aged | Male | Epirubicin - administration & dosage | Mastectomy, Modified Radical | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Carcinoma, Ductal, Breast - drug therapy | Antineoplastic Agents, Hormonal - therapeutic use | Chemotherapy, Adjuvant | Methotrexate | Radiotherapy, Adjuvant | Gonadotropin-Releasing Hormone - agonists | Carcinoma, Ductal, Breast - secondary | Fluorouracil | Aromatase Inhibitors - administration & dosage | Neoplasms, Hormone-Dependent - surgery | Goserelin - administration & dosage | Carcinoma, Ductal, Breast - surgery | Estrogen Receptor Modulators - administration & dosage | Kaplan-Meier Estimate | Carcinoma, Papillary - drug therapy | Combined Modality Therapy | Breast Neoplasms, Male - drug therapy | Carcinoma, Papillary - surgery | Breast Neoplasms, Male - radiotherapy | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Ductal, Breast - radiotherapy | Aged | Neoplasms, Hormone-Dependent - drug therapy | Progesterone | Care and treatment | Pituitary hormones | Development and progression | Breast cancer | Metastasis | Gonadotropin | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 3, pp. 229 - 237
Purpose Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely... 
THERAPY | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | TESTOSTERONE | ADENOCARCINOMA | GROWTH | RECEPTOR | RADICAL PROSTATECTOMY | CASTRATION | SPLICE VARIANTS | DIHYDROTESTOSTERONE | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Androgen Receptor Antagonists - therapeutic use | Ketoconazole - administration & dosage | Humans | Middle Aged | Receptors, Androgen - metabolism | Male | Prostate - metabolism | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - therapeutic use | Dihydrotestosterone - blood | Aged, 80 and over | Androsterone - blood | Biomarkers, Tumor - metabolism | Prostatic Neoplasms - blood | Chemotherapy, Adjuvant | Testosterone - blood | Molecular Targeted Therapy - methods | Prostatic Neoplasms - drug therapy | Dihydrotestosterone - metabolism | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Treatment Outcome | Prostate-Specific Antigen - blood | Pilot Projects | Azasteroids - administration & dosage | Receptors, Androgen - genetics | Anilides - administration & dosage | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | 5-alpha Reductase Inhibitors - administration & dosage | Androgen Antagonists - therapeutic use | Dutasteride | Aged | Neoplasm Staging | ORIGINAL REPORTS | To16
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 345 - 352
Journal Article